Diabetes mellitus (DM) has been regarded as an equivalent risk factor as coronary artery disease1 and is present in nearly 25% of patients who receive percutaneous coronary intervention (PCI).2 DM is shown as an adverse predictor for major adverse cardiac events (MACE) after PCl in bare metal stent (BMS) era.3 Recently, clinical trials have demonstrated the favorable tendency of using drug-eluting stents (DES) in treating diabetic patients with coronary artery disease.4,5 This study compared the clinical outcomes between the diabetic patients receiving DES with those receiving BMS in China.